Shares of GlaxoSmithKline plc (LON:GSK) have been given a consensus recommendation of “Hold” by the twenty-two analysts that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is GBX 1,578.50 ($21.41).
A number of brokerages have issued reports on GSK. Liberum Capital reiterated a “buy” rating and set a GBX 1,760 ($23.87) price objective on shares of GlaxoSmithKline in a research note on Wednesday, October 25th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a GBX 1,570 ($21.29) price objective on shares of GlaxoSmithKline in a research note on Monday, October 2nd. Beaufort Securities reiterated a “buy” rating and set a GBX 1,800 ($24.41) price objective on shares of GlaxoSmithKline in a research note on Monday, October 23rd. UBS Group upgraded GlaxoSmithKline to a “buy” rating and set a GBX 1,550 ($21.02) price target for the company in a research note on Monday, November 27th. Finally, Societe Generale restated a “sell” rating on shares of GlaxoSmithKline in a research note on Thursday, November 9th.
In other GlaxoSmithKline news, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($17.77), for a total transaction of £262,000 ($355,302.41). Also, insider Urs Rohner purchased 473 shares of the business’s stock in a transaction on Wednesday, October 25th. The shares were bought at an average cost of GBX 1,518 ($20.59) per share, with a total value of £7,180.14 ($9,737.10). Insiders have acquired 502 shares of company stock valued at $756,702 in the last three months.
GlaxoSmithKline (LON:GSK) last announced its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The business had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%.
The business also recently declared a dividend, which was paid on Thursday, January 11th. Shareholders of record on Thursday, November 9th were issued a dividend of GBX 19 ($0.26) per share. This represents a yield of 1.41%. The ex-dividend date of this dividend was Thursday, November 9th.
COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline plc (GSK) Receives Average Recommendation of “Hold” from Brokerages” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://stocknewstimes.com/2018/02/11/glaxosmithkline-plc-gsk-receives-average-recommendation-of-hold-from-brokerages.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.